Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:hospital
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Symdeko
|
| gptkbp:aims_to |
best practices
patient care healthcare costs treatment efficacy |
| gptkbp:analyzes |
biomarkers
long-term effects of treatments |
| gptkbp:collaborates_with |
research institutions
|
| gptkbp:collaborations |
internationally
|
| gptkbp:collection |
patient outcomes
|
| gptkbp:conducted |
informed consent
multiple countries several years clinical research organizations |
| gptkbp:contributed_to |
medical knowledge
|
| gptkbp:focuses_on |
evidence-based medicine
evolution of treatment strategies |
| gptkbp:follows |
gptkb:legislation
|
| gptkbp:has |
defined endpoints
|
| https://www.w3.org/2000/01/rdf-schema#label |
EVOLVE study
|
| gptkbp:includes |
follow-up assessments
placebo group |
| gptkbp:involves |
multidisciplinary teams
data monitoring committees patient participants |
| gptkbp:is_analyzed_in |
qualitative methods
safety and efficacy |
| gptkbp:is_designed_to |
gptkb:hospital
test hypotheses |
| gptkbp:is_evaluated_by |
independent reviewers
|
| gptkbp:is_part_of |
larger research initiatives
clinical guidelines development |
| gptkbp:is_reviewed_by |
ethics committees
|
| gptkbp:is_subject_to |
regulatory oversight
|
| gptkbp:is_supported_by |
patient advocacy groups
|
| gptkbp:led_to |
principal investigators
|
| gptkbp:measures |
quality of life
|
| gptkbp:provides |
data for meta-analyses
|
| gptkbp:published_by |
peer-reviewed journals
medical journals |
| gptkbp:receives_funding_from |
government grants
|
| gptkbp:registration |
clinical trial registries
|
| gptkbp:reports_to |
annual conferences
regulatory agencies adverse events |
| gptkbp:sponsor |
pharmaceutical companies
|
| gptkbp:targets |
specific diseases
|
| gptkbp:uses |
statistical analysis methods
|
| gptkbp:utilizes |
surveys and questionnaires
randomized controlled trial design |